Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) — Net Asset Quality Index
Drugs Made In America Acquisition Corp. Ordinary Shares (DMAA) has a Net Asset Quality Index of 96.9% as of March 2026. This metric measures the proportion of total assets financed by shareholders' equity — total assets of $242.04 Million minus total liabilities of $7.39 Million yields net assets of $234.64 Million. A higher index indicates a stronger, lower-leverage balance sheet. See Drugs Made In America Acquisition Corp. (DMAA) defensive interval to measure how many days the company can operate on defensive assets alone.
Quality Index
Net Assets
Total Assets
Total Liabilities
Drugs Made In America Acquisition Corp. Ordinary Shares Net Asset Quality Index Over Time (2024–2025)
This chart shows how Drugs Made In America Acquisition Corp. Ordinary Shares's Net Asset Quality Index has evolved across 2 annual periods from 2024 to 2025. As of March 2026, the index stands at 96.9%, representing net assets of $234.64 Million against total assets of $242.04 Million USD. Explore DMAA cash generation efficiency to assess how effectively this company generates cash.
Annual Net Asset Quality Index for Drugs Made In America Acquisition Corp. Ordinary Shares (2024–2025)
The table below presents the year-by-year Net Asset Quality Index for Drugs Made In America Acquisition Corp. Ordinary Shares from 2024 to 2025, covering 2 annual filings. Each row shows total assets, total liabilities, net assets, the quality index percentage, and the change in percentage points compared to the prior year. For market capitalisation and the full company profile, see DMAA stock market capitalisation.
| Year | Quality Index | Net Assets (USD) | Total Assets | Total Liabilities | Change (pp) |
|---|---|---|---|---|---|
| 2025 | 97.0% | $232.64 Million | $239.92 Million | $7.28 Million | ▲ +141.4 pp |
| 2024 | -44.5% | $-244.85 | $550.82 | $795.67 | — |